A maker of scientific instruments used by biomedical researchers to study individual cells and proteins. Its three platforms—CyTOF mass cytometry, Hyperion spatial proteomics, and Biomark genomics—are sold to academic labs, translational centers, and biopharma companies. Founded in 1999 as Mycometrix and renamed Fluidigm in 2001 (a play on the "fluid" microchips it builds), the company became Standard BioTools in 2022, after its microfluidics "integrated fluidic circuits" were born from a Caltech lab that manipulates fluids on chips much like electronics handle electrons.
Standard BioTools swung to a $26.8M net loss as $14.7M in Treeline merger costs erased operating improvements.
The pending merger with Treeline Biosciences reshaped the quarter. fell 8% to $20.1 million and the operating loss narrowed to $25.4 million on cost cuts, but $14.7 million in transaction costs drove a net loss of $26.8 million. The company is now a life-sciences tools provider preparing to become a biopharmaceutical firm, with $544 million in cash and a Nasdaq delisting deadline in January 2027.
Key takeaways
A $14.7 million charge for transaction and integration expenses, almost entirely tied to the all-stock merger agreement with Treeline Biosciences, was the single largest driver of the quarter's $26.8 million net loss.
from continuing operations fell 8% to $20.1 million, driven by a 10% decline in consumables and an 8% decline in services, while instrument revenue was flat.
improved 3.6 percentage points to 52.4% as cost of fell faster than revenue, with service costs down 21%.
Section summaries
Management's Discussion and Analysis
Q2 2026 revenue fell 8% to $20.1M; operating loss narrowed on cost cuts, but transaction costs from the pending Treeline merger drove a net loss.
⌄
Total declined 8% to $20.1M in Q2 2026, driven by a 10% drop in consumables and an 8% drop in services; instrument revenue was flat.
improved to 52.4% from 48.8% as cost of fell faster than revenue, with service costs down 21%.
R&D expense fell 68% to $2.0M and SG&A fell 42% to $16.4M, primarily from 2025 restructuring-related personnel cost reductions.
Operating expenses fell 42% to $35.9 million, with R&D down 68% to $2.0 million and SG&A down 42% to $16.4 million, primarily from personnel cost reductions following the 2025 restructuring that eliminated approximately 20% of the global workforce.
Cash, equivalents, and short-term investments rose to $544.0 million at quarter-end, up from $237.1 million a year earlier, boosted by $388.2 million in net proceeds from the January 2026 sale of the SomaScan Business to Illumina.
The company received a Nasdaq deficiency notice in April 2026 for failing the $1.00 minimum bid price rule and has until January 19, 2027, to regain compliance or face delisting.
What changed
The SomaScan sale to Illumina, flagged in Q2 FY2025 as pending, closed on January 30, 2026, yielding $363.2 million in net cash proceeds and a $172.3 million gain recorded in Q1 FY2026.
The risk flagged repeatedly since Q1 FY2025 did not materialize this quarter; the company did not record an charge.
The 33% decline in instrument in Q1 FY2026 moderated to flat in Q2, suggesting the prior quarter's drop was not the start of a sustained slide.
The consumables decline deepened from a 17% drop in Q3 FY2025 to 10% in Q2 FY2026, an improvement in trajectory but still negative, leaving the question of a sustained pullback unresolved.
The Nasdaq delisting risk escalated: the deficiency notice received in April 2026 gives the company until January 19, 2027, to regain compliance, a deadline that now overlaps with the expected Treeline merger close.
What to watch
Whether the Treeline merger closes as expected, or whether the company pays a $16.1 million termination fee and up to $5 million in expense reimbursement, and potentially faces dissolution.
Whether the company regains compliance with the Nasdaq $1.00 minimum bid price by January 19, 2027, and whether a reverse stock split is pursued if the stock price does not recover.
The trajectory of consumables in Q3 FY2026, to determine whether the 10% decline in Q2 represents a stabilizing trend or a continued erosion of the core business.
The outcome of the fiduciary-duty bench trial set for March 2027 over the SomaLogic merger, and whether any settlement or adverse ruling creates a material cash outflow.
Transaction and integration expenses surged to $14.7M from $0.3M, almost entirely tied to the all-stock merger agreement with Treeline Biosciences.
Cash and investments stood at $544.0M at quarter-end, boosted by $388.2M in net proceeds from the January 2026 sale of the SomaScan Business.
The company expects existing liquidity to fund operations for at least 12 months and must divest or wind down its Legacy Business under the merger terms.
Quantitative and Qualitative Disclosures About Market Risk
Primary market risks are interest rate and foreign exchange; the company does not hedge FX and reported a $4.8M loss in H1 FY2026.
⌄
Cash equivalents in checking and money market accounts expose the company to interest rate risk, with capital preservation as the stated investment objective.
Foreign currency exposure arises from non-U.S. operations and is not hedged; a $4.8M loss was recognized in the six months ended June 30, 2026, versus a $1.9M gain in the prior-year period.
The company states inflation has not materially affected the business in the last two years but expects appreciable increases in labor and other operating costs if global inflation persists.
Future securities offerings are cited as a possible funding source, exposing the company to capital market risk tied to stock price and market conditions.
Information with respect to certain legal proceedings is included in Note 6 to our accompanying financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
⌄
Information with respect to certain legal proceedings is included in Note 6 to our accompanying financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Key risks center on Nasdaq delisting, the pending Treeline merger, and post-merger business transformation.
⌄
The company faces Nasdaq delisting after again failing the $1.00 minimum bid price rule, with a compliance deadline of January 19, 2027.
The pending merger with Treeline may not close, risking a $16.1M termination fee, up to $5M in expense reimbursement, and potential dissolution.
Merger completion would transform the company from a life sciences tools provider into a clinical-stage biopharmaceutical firm, altering its investor base and stock volatility.
Post-merger, current stockholders would own only ~16% of the combined company, and the new board and management would be dominated by Treeline designees.
The merger's fluctuates with Parent Net Cash, and the value of depends entirely on uncertain future monetization of legacy assets.
The company's ability to use its may be severely limited by the ownership change triggered by the merger.